Engineered T-Cell Therapy

Engineered T cells are the result of turning a therapeutic process into a product capable of overcoming checkpoint inhibition, and are the future of adoptive immunotherapy. Cytokine release syndrome,” a storm of molecules generated as the cells fights the cancer. Instead of an antibody, single-chain target domain, he used a human cytokine, IL-13, with a mutation in the sequence that gave high affinity for IL-13 receptor α2. These cells were infused intra cranially, establishing the safety of intracranial administration with some antitumor responses.

 

    Related Conference of Engineered T-Cell Therapy

    July 29-30 2019

    6th International Conference on Parasitology & Microbiology

    Amsterdam, Netherlands
    July 29-30, 2019

    11th Global Summit on Immunology and Cell Biology

    Sydney, Australia
    November 12-13, 2019

    13th International Congress on Autoimmunity

    Brisbane, Australia
    November 14-15, 2019

    International Conference on Vaccines and Immune Response

    Istanbul, Turkey
    November 14-15, 2019

    Annual Congress on Antibiotics and Antimicrobial Resistance

    Geneva, Switzerland
    November 21-22, 2019

    World Conference on Vaccine and Immunology

    Dubai, UAE

    Engineered T-Cell Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in